Today: 8 February 2026
Subscribe
Browse Category

Stock Market News 5 January 2026

Applied Materials stock hits a fresh record — what’s driving AMAT’s outsized rally today

Applied Materials stock hits a fresh record — what’s driving AMAT’s outsized rally today

Applied Materials shares jumped 6.7% to $286.96, hitting a record $287.68 Monday as chip-equipment stocks rallied. ASML climbed after a Bernstein upgrade, while Lam Research and KLA also gained. The moves come ahead of Friday’s U.S. jobs report, which could shift rate expectations. Applied faces ongoing risk from U.S. export curbs that may cut $600 million from 2026 revenue.
5 January 2026
··
Coinbase stock jumps after Goldman upgrade as Bitcoin trades near $94,000 — what investors watch next

Coinbase stock jumps after Goldman upgrade as Bitcoin trades near $94,000 — what investors watch next

Coinbase shares climbed over 7% to $253.63 Monday after Goldman Sachs upgraded the stock to “buy” and raised its price target to $303. Bitcoin’s 2.6% rebound also boosted crypto-linked stocks, with Robinhood up 6%. Traders now await Friday’s U.S. jobs report and Coinbase’s earnings update in February.
5 January 2026
·····
Bloom Energy stock jumps again: BE extends rally on $600 million Wells Fargo credit line as jobs report looms

Bloom Energy stock jumps again: BE extends rally on $600 million Wells Fargo credit line as jobs report looms

Bloom Energy shares rose 6.3% to $104.95 in mid-morning trading Monday, after closing at $98.69 Friday. The move comes as attention shifts to Bloom’s $600 million revolving credit facility with Wells Fargo, secured by most company assets and maturing in 2030. The facility allows flexible borrowing but carries floating-rate costs and leverage restrictions. Other fuel-cell stocks were mixed, while major indexes traded higher.
5 January 2026
·
UnitedHealth stock ticks up after Barclays target hike as UNH earnings near

UnitedHealth stock ticks up after Barclays target hike as UNH earnings near

UnitedHealth shares rose 0.8% to $338.94 in late-morning trading Monday after Barclays raised its price target to $391 and reiterated an Overweight rating. Investors are watching ahead of Jan. 27, when UnitedHealth will report 2025 results and 2026 guidance. Scrutiny remains on medical-cost trends, operational review progress, and ongoing Justice Department investigations into Medicare Advantage billing.
5 January 2026
·····
AAOI stock slides 8% as Applied Optoelectronics gives back Friday rally on AI optics trade

AAOI stock slides 8% as Applied Optoelectronics gives back Friday rally on AI optics trade

Applied Optoelectronics shares dropped 8% to $36.43 Monday after opening at $41.05, reversing a sharp gain from Friday. The decline came as optical and networking stocks fell broadly, even as the Dow and Nasdaq rose. In December, the company announced its first large order for 800G data-center transceivers, expected to add $4–8 million to Q4 revenue. The company forecast Q4 revenue of $125–$140 million.
5 January 2026
··
Goldman Sachs stock hits a record high as Venezuela shock lifts Dow; payrolls and earnings in focus

Goldman Sachs stock hits a record high as Venezuela shock lifts Dow; payrolls and earnings in focus

Goldman Sachs shares hit a record high Monday, rising 4.3% to $953.61 after a U.S. military strike captured Venezuelan President Nicolas Maduro. The move lifted the Dow to an all-time high as financial and energy stocks rallied. Oil prices steadied near $61 a barrel. Traders are watching Friday’s U.S. jobs report and Goldman’s January 15 earnings for further direction.
5 January 2026
··
Rocket Lab stock slips after rally as insider sale filing surfaces; Neutron timing in focus

Rocket Lab stock slips after rally as insider sale filing surfaces; Neutron timing in focus

Rocket Lab shares fell 0.7% to $75.43 by late Monday morning after a recent surge driven by an $816 million U.S. Space Development Agency satellite contract. A Form 144 filing showed COO Frank Klein plans to sell up to 100,000 shares. Cantor Fitzgerald reiterated an Overweight rating and a $72 target. Rocket Lab is expected to report earnings around Feb. 26.
5 January 2026
··
Bed Bath & Beyond stock jumps as Marcus Lemonis becomes CEO and pitches “Everything Home” plan

Bed Bath & Beyond stock jumps as Marcus Lemonis becomes CEO and pitches “Everything Home” plan

Bed Bath & Beyond appointed Marcus Lemonis as CEO, effective Jan. 1, replacing Alexander Thomas, whose employment ended the same day. Shares rose nearly 5% in premarket trading. Lemonis outlined a strategy expanding into financial services and home transaction platforms, and said the Kirkland’s deal could add $350 million in net revenue. The company reported a 90% year-over-year improvement in net loss for Q3 2025.
5 January 2026
·
Baidu stock slides as Kunlunxin Hong Kong IPO plan shifts focus to timing, approvals

Baidu stock slides as Kunlunxin Hong Kong IPO plan shifts focus to timing, approvals

Baidu’s U.S. shares fell 3.7% to $144.75 Monday after its AI chip unit, Kunlunxin, filed for a Hong Kong listing and received exchange approval to proceed with a spin-off. Baidu said Kunlunxin will remain a subsidiary after the deal, but did not disclose offering size or timeline. Jefferies raised its Baidu price target to $181, estimating Kunlunxin’s valuation at up to $23 billion.
5 January 2026
···
Applied Digital (APLD) stock jumps 6% as earnings loom and ChronoScale deal stays in focus

Applied Digital (APLD) stock jumps 6% as earnings loom and ChronoScale deal stays in focus

Applied Digital shares climbed 6.3% to $29.88 Monday, ahead of fiscal Q2 results due Jan. 7 and updates on North Dakota AI data center projects. Short interest stands at 34% of float, heightening volatility. The stock touched $30.11 intraday, while the Nasdaq 100 rose 1%. Investors await details on lease revenue conversion and data center buildout timelines.
5 January 2026
···
Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

Eli Lilly shares dropped 3.4% to $1,043.14 after Novo Nordisk launched U.S. sales of an oral Wegovy weight-loss pill starting at $149 a month. Novo’s move intensified focus on pricing in the obesity drug market. The Health Care Select Sector SPDR ETF fell 1.3%, while Novo Nordisk shares rose 2.9%. Investors are awaiting Lilly’s next earnings update on February 4.
5 January 2026
···
CleanSpark stock jumps 7% as bitcoin rallies; miners rise with February earnings in view

CleanSpark stock jumps 7% as bitcoin rallies; miners rise with February earnings in view

CleanSpark shares climbed about 7% to $12.37 Monday as bitcoin hovered near $94,000, boosting U.S.-listed miners. JPMorgan flagged a second straight monthly drop in bitcoin network hashrate, now averaging 1,045 EH/s in December. Peers Marathon Digital and Riot Platforms also gained. CleanSpark’s next quarterly report is due Feb. 5.
5 January 2026
·····
1 … 478 479 480 481 482 … 1,174

Stock Market Today

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

7 February 2026
Disney shares closed up 3.6% at $108.70 Friday, recovering from earlier losses as U.S. stocks rallied and the Dow topped 50,000. Investors are watching Super Bowl streaming economics and Disney’s CEO transition, with Josh D’Amaro set to take over at the March 18 meeting. Disney reported quarterly revenue of $25.98 billion and adjusted EPS of $1.63, while segment operating income fell 9% to $4.6 billion.
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

7 February 2026
Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
Go toTop